Calyx announced today that it partnered with Qynapse to use AI-powered neuroimaging analysis technology for central nervous system disorders.
The partnership will combine Calyx’s eClinical and regulatory solutions and services with Qynapse’s artificial intelligence (AI)-based QyScore and QyPredict platforms for customers developing medical treatments for central nervous system (CNS) disorders.
“We’re delighted to add Qynapse’s advanced analysis capabilities to our full suite of proven medical imaging services,” Calyx CMO Dr. Stephen M. Bravo said in a news release. “This groundbreaking services and technology partnership will enable our clients to more confidently assess the full potential of treatments in development for Multiple Sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s disease, as well as other neurodegenerative disorders.”
Qynapse developed a large dataset of proprietary algorithms for rapidly analyzing and interpreting brain …